Immunocine Cancer Center

12/03/2026

Three years after completing treatment at Immunocine for Stage 2C/III Melanoma, Kevin is living life on his own terms again.

In this update, Kevin shares what life looks like years after his initial diagnosis, with no evidence of disease and no ongoing treatment. From walking his daughter to her first day of school to spending weekends at dirt bike races with his son, he reflects on the milestones that once felt uncertain and the perspective that comes from facing cancer head-on.

Today, Kevin is back to running his excavation business, planning for the future, and showing up fully for his family. While cancer remains part of his story, it no longer defines his present.

You can watch the full conversation here:

Three years after completing treatment at Immunocine for Stage 2C/III Melanoma, Kevin is living life on his own terms again.In this update, Kevin shares what...

11/03/2026

Three years ago, Kevin was navigating one of the most uncertain times of his life. After a Stage 2C melanoma diagnosis and a recurrence that forced him to look beyond standard options, he made the decision to pursue treatment in at Immunocine.

Watch the full interview here: https://youtu.be/TTruWg4yAmo

At the time, the focus was survival and response. Today, the focus is something entirely different. It is stability, family, and the quiet return to everyday life.

Thank you, Kevin, for continuing to share your story and inspire others.

26/02/2026

It may seem like a basic question, but its an important one: what is immunotherapy? At its core, immunotherapy is any treatment designed to educate and or active your immune system to eliminate a threat.

We answer even more of your FAQs about Immunocine on our YouTube channel.

https://www.youtube.com/watch?v=R1DH55tN6PU

24/02/2026

In 2022, Kevin was diagnosed with Stage 2C Melanoma Cancer. Despite undergoing multiple surgeries and treatments in Toronto, Kevin’s condition stubbornly resurfaced, leaving him and his young family facing an uncertain future.

In April 2023, Kevin embarked on the six-week treatment protocol at our center in Cancun. Just two months later, his oncologist in Toronto was astounded by the remarkable progress.

He credits the IDCT with not just saving his life, but also giving him a future to look forward to.

Ahead of our latest check-in with Kevin - an incredible 3 years post treatment - we are taking a look back at his story through the years. You can watch this short film about his journey 1 year post treatment here:

From flying through the air on dirt bikes to operating heavy machinery, Kevin has always thrived in high-risk environments. But in 2022, he faced his greates...

21/02/2026

Kevin was diagnosed with a rare melanoma in June 2022. After initial success with surgery and standard treatments, the cancer returned, leaving Kevin and his family scouring the globe for alternative treatments, leading them to discover Dendritic Cell treatment and ultimately Immunocine. Kevin began the IDCT protocol in April 2023. By June 2023, the effects of the treatment were undeniable. The treatment had not just worked; it was a resounding success.

Ahead of our latest check-in with Kevin - an incredible 3 years post treatment - we are taking a look back at his story though the years. This interview was filmed in March 2024.

16/02/2026

A fair question is: why is Immunocine in Cancun, Mexico? This treatment is currently going through the regulatory process and until such time we are not able to widely offer this. We needed to look for locations that could safely and correctly offer this to patients today. Because when it comes to cancer, time is everything.

We answer even more of your FAQs about Immunocine on our YouTube channel.

13/02/2026

Whether you’ve followed Immunocine from the start or are just joining us, we’re grateful you’re here.

Our CEO and founder, Matt Halpert, delivered a welcome speech at the recent Immunocine Summit that serves as a great (re-)introduction for who we are.

At Immunocine, we’re focused on a fundamental problem in cancer care: many patients don’t have an immune system that’s effectively responding to their cancer. Rather than concentrating only on what causes cancer, we’re asking why the immune system isn’t eliminating it, and how we can help change that.

That starts with the science. And the Immunocine Dendritic Cell Treatment (IDCT) protocol. This is the first treatment of its kind to “Double Load” the patient’s Dendritic Cells with their extracted cancer cells. Using this completely new approach, our treatment is able to not only generate a natural immune response, but one that is comprehensive enough to attack a patient’s cancer throughout their body.

The future of cancer treatment is right here, right now.

07/02/2026

A big thank you to our amazing team and partners who presented at the Immunocine Summit. It’s so important that our community hears directly from the people doing the work and driving what’s next at Immunocine. We can’t wait to share more of their insights with all of you in the weeks to come.

06/02/2026

A great start to the year with our team, our patients, and our extended Immunocine community at the Immunocine Summit in Cancun this past weekend! We’re grateful for the chance to connect, listen, and engage in meaningful conversations about our treatment approach and patient care. Hearing diverse perspectives and sharing what’s next for Immunocine made this time especially energizing. So much to look forward to.

05/02/2026

Immunocine’s treatment is truly one-of-a-kind, and we know you might have questions about how it works. In this video, Dr. Matt Halpert breaks down what makes our Immunocine Dendritic Cell Treatment (IDCT) protocol unique.

We answer even more of your FAQs about Immunocine on our YouTube channel.

02/02/2026

In today’s world, chronic inflammation is an ever-present challenge linked to serious diseases, notably cancer. However, the paradox arises when we consider immunotherapy—a treatment harnessing inflammation to combat cancer. The key to understanding this complex interplay lies in precise “targeting” of the immune system’s arsenal.

Taken all together, the concept of “inflammation” is not straight forward and cannot be simply lumped into a “helpful” or “hurtful” category.

Read the full article here: https://immunocine.com/inflammation-in-cancer/